Zobrazeno 1 - 10
of 43
pro vyhledávání: '"D. G. Kozlov"'
Publikováno v:
Applied Biochemistry and Microbiology. 58:854-863
Autor:
E. S. Bobrov, A. Yu. Gorbunova, E. P. Sannikova, I. I. Gubaidullin, O. M. Ignatova, M. Yu. Kopaeva, N. V. Bulushova, D. G. Kozlov
Publikováno v:
Applied Biochemistry and Microbiology. 58:976-983
Autor:
P. I. Akentyev, I. Yu. Filippova, Nikita I. Zhiganov, Valeriia F. Tereshchenkova, I. I. Gubaidullin, N. V. Belyaeva, D. G. Kozlov, Elena N. Elpidina
Publikováno v:
Applied Biochemistry and Microbiology. 57:579-585
Pseudoenzymes are homologs of active enzymes that have amino acid substitutions in the active center and, therefore, usually do not possess enzymatic activity. In this work, a recombinant proprotein (proSerPH122) of the homolog of serine peptidases o
Publikováno v:
Applied Biochemistry and Microbiology. 56:770-778
The ability of yeast to produce highly active variants of the recombinant phospholipase PLA2 is confirmed. Highly active variants were based on an original enzyme from the Streptomyces violaceoruber А-2688 strain. Various approaches to reduce enzyme
Publikováno v:
Applied Biochemistry and Microbiology. 56:861-869
Mutant variants of mini-intein PRP8 from Penicillium chrysogenum (Int4b) with improved control of C-terminal processing are characterized. The studied variants can serve as the basis for the self-removal of polypeptide tags that can carry an affine l
Autor:
D. G. Kozlov, S. E. Cheperegin, A. V. Malysheva, B. D. Efremov, I. I. Gubaidullin, E. P. Sannikova
Publikováno v:
Applied Biochemistry and Biotechnology. 193:1351-1364
Phospholipase A2 (PLA2) has found extensive use in industry. However, recombinant PLA2 production in different expression systems is a difficult task because of its toxicity to cell membranes. We report here the development of an effective method for
Publikováno v:
Bulletin of Experimental Biology and Medicine. 169:53-56
The study compared effectiveness of intranasal administration of glypin (human recombinant modified glucagon-like peptide-1) and reference drug Victoza in BALB/c mice. The minimum effective dose of intranasal glypin was 0.5 mg/kg, and a 2-fold elevat
Autor:
I. I. Gubaidullin, P. I. Akentyev, D. G. Kozlov, Elena N. Elpidina, Valeriia F. Tereshchenkova, Nikita I. Zhiganov
Publikováno v:
Biotekhnologiya. 36:78-86
A strain of the Komagataella kurtzmanii yeast, a producer of recombinant peptidase SerP38 from the yellow mealworm Tenebrio molitor, has been obtained. The level of the pro-enzyme secretion was 20-50 mg/L. It was shown that, during secretion in yeast
Publikováno v:
Applied Biochemistry and Microbiology. 55:846-849
It is shown that, unlike eukaryotic ubiquitin-specific proteinases (deubiquitinating enzymes, DUBs), the E. coli deubiquitinase ElaD can process sites containing not only GlyGly but also GlyAla with equal efficiency. At the same time, the bacterial e
Autor:
T. S. Gracheva, F. A. Klebanov, E. P. Sannikova, S. V. Yarotskii, I. A. Zalunin, V. L. Yurin, S. E. Cheperegin, N. V. Rykalina, E. V. Askerova, N. V. Bobkova, D. G. Kozlov, N. V. Bulushova, O. G. Tatarnikova
Publikováno v:
Applied Biochemistry and Microbiology. 55:722-732
An1 original drug, Glypin, has been developed for the treatment of type-II human diabetes mellitus. Its active pharmaceutical substance is a completely biosynthetic, recombinant, modified, human glucagon-like peptide (rmGlp-1) obtained via culturing